{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:11:49Z","timestamp":1779804709631,"version":"3.53.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pharos University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The T lymphocytes have a vital role in tumor immunosurveillance within the tumor microenvironment (TME) but on the other hand, the TME adopts several mechanisms that cause inhibition and apoptosis to effector T cells leading to tumor immune evasion. The controversial role of interleukin-2 (IL-2) was demonstrated by promoting the activation and proliferation of different immune cells such as NK cells, effector and regulatory T cells (T regs). Thus, ex-vivo approach was used to investigate IL-2 anti-tumor effect on breast cancer cells isolated from Egyptian patients after mastectomy via modulating Treg\/CTLA-4\/Blimp-1\/caspase-3 trajectory. Previous to the ex-vivo approach we aimed to find common targets between IL-2 and breast cancer disease using network pharmacology. Results of network pharmacology illustrated that there were 35 common targets including CD4, CTLA-4 and caspase 3. Breast cancers cells obtained were then cultured in the presence of 10\u00a0\u00b5l of (50 ng\/ml) recombinant IL-2 for 24\u00a0h. Results revealed that tissue culture supplementation with IL-2 significantly reduced T regs within the TME via inhibiting the tumor expression of CD25 and Forkhead box P3 (FOXP3). In addition, it was found that IL-2 significantly decreased the expression of the inhibitory receptor CTLA-4 and increased the expression of B lymphocyte\u2013induced maturation protein-1(Blimp-1), leading to the activation of effector T cells and the induction apoptosis of the breast tumor cells. These findings suggest that IL-2 could serve as a new treatment strategy for breast cancer via modulating immune responses within the TME.<\/jats:p>","DOI":"10.1038\/s41598-026-52551-2","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:07:11Z","timestamp":1779768431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating network pharmacology with ex-vivo analysis to assess the effect of IL-2 in halting breast cancer: involvement of Treg\/CTLA-4\/Blimp-1\/caspase-3"],"prefix":"10.1038","volume":"16","author":[{"given":"Seham Abou","family":"Shousha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3467-5172","authenticated-orcid":false,"given":"Sherihan Salaheldin Abdelhamid","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hend","family":"Kadry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman Ahmed","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"qabany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira A.","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atef","family":"Metwea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan A.","family":"Baheeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Shahine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"3","key":"52551_CR1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/14737159.2018.1439382","volume":"18","author":"S Mittal","year":"2018","unstructured":"Mittal, S., Brown, N. J. & Holen, I. The breast tumor microenvironment: Role in cancer development, progression and response to therapy. Expert Rev. Mol. Diagn. 18(3), 227\u2013243 (2018).","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"6","key":"52551_CR2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi, Y., Shitara, K. & Nishikawa, H. Regulatory T cells in cancer immunosuppression\u2014implications for anticancer therapy. Nat. Rev. Clin. Oncol. 16(6), 356\u2013371 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"19","key":"52551_CR3","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1182\/blood-2011-11-392324","volume":"119","author":"T Duhen","year":"2012","unstructured":"Duhen, T., Duhen, R., Lanzavecchia, A., Sallusto, F. & Campbell, D. J. Functionally distinct subsets of human FOXP3\u2009+\u2009Treg cells that phenotypically mirror effector Th cells. Blood 119(19), 4430\u201340 (2012).","journal-title":"Blood"},{"key":"52551_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00262-013-1490-y","volume":"63","author":"TL Whiteside","year":"2014","unstructured":"Whiteside, T. L. Regulatory T cell subsets in human cancer: Are they regulating for or against tumor progression?. Cancer Immunol. Immunother. 63, 67\u201372 (2014).","journal-title":"Cancer Immunol. Immunother."},{"key":"52551_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02156-y","volume":"23","author":"A Zhang","year":"2024","unstructured":"Zhang, A. et al. Regulatory T cells in immune checkpoint blockade antitumor therapy. Mol. Cancer 23, 251. https:\/\/doi.org\/10.1186\/s12943-024-02156-y (2024).","journal-title":"Mol. Cancer"},{"key":"52551_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1328193","volume":"15","author":"O Goldmann","year":"2024","unstructured":"Goldmann, O., Nwofor, O. V., Chen, Q. & Medina, E. Mechanisms underlying immunosuppression by regulatory cells. Front. Immunol. 15, 1328193. https:\/\/doi.org\/10.3389\/fimmu.2024.1328193 (2024).","journal-title":"Front. Immunol."},{"issue":"4","key":"52551_CR7","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1159\/000464429","volume":"41","author":"AM Westendorf","year":"2017","unstructured":"Westendorf, A. M. et al. Hypoxia enhances immunosuppression by inhibiting CD4\u2009+\u2009effector T cell function and promoting Treg activity. Cell. Physiol. Biochem. 41 (4), 1271\u20131284 (2017).","journal-title":"Cell. Physiol. Biochem."},{"issue":"4","key":"52551_CR8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1158\/1541-7786.MCR-21-0405","volume":"20","author":"YF Chen","year":"2022","unstructured":"Chen, Y. F. et al. O-GlcNAcylation of Blimp-1 in lymphocytes inhibits its transcriptional function and is associated with migration and invasion of breast cancer cells. Mol. Cancer Res. 20(4), 650\u2013660. https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0405 (2022).","journal-title":"Mol. Cancer Res."},{"key":"52551_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-017-0354-8","volume":"24","author":"SH Fu","year":"2017","unstructured":"Fu, S. H., Yeh, L. T., Chu, C. C., Yen, B. L. & Sytwu, H. K. New insights into Blimp-1 in T lymphocytes: A divergent regulator of cell destiny and effector function. J. Biomed. Sci. 24, 1\u20137 (2017).","journal-title":"J. Biomed. Sci."},{"key":"52551_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108515","volume":"218","author":"J Damoiseaux","year":"2020","unstructured":"Damoiseaux, J. The IL-2\u2013IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor. Clin. Immunol. 218, 108515 (2020).","journal-title":"Clin. Immunol."},{"issue":"68","key":"52551_CR11","doi-asserted-by":"publisher","first-page":"eabl6322","DOI":"10.1126\/sciimmunol.abl6322","volume":"7","author":"SM Kahan","year":"2022","unstructured":"Kahan, S. M. et al. Intrinsic IL-2 production by effector CD8 T cells affects IL-2 signaling and promotes fate decisions, stemness, and protection. Sci. Immunol. 7 (68), eabl6322 (2022).","journal-title":"Sci. Immunol."},{"issue":"3","key":"52551_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1158\/2326-6066.CIR-15-0009","volume":"3","author":"TA Waldmann","year":"2015","unstructured":"Waldmann, T. A. The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: Implications for cancer therapy. Cancer Immunol. Res. 3(3), 219\u2013227 (2015).","journal-title":"Cancer Immunol. Res."},{"issue":"50","key":"52551_CR13","doi-asserted-by":"publisher","first-page":"48344","DOI":"10.1021\/acsomega.3c07782","volume":"8","author":"NM Alotaibi","year":"2023","unstructured":"Alotaibi, N. M., Alotaibi, M. O., Alshammari, N., Adnan, M. & Patel, M. Network pharmacology combined with molecular docking, molecular dynamics, and in vitro experimental validation reveals the therapeutic potential of Thymus vulgaris L. essential oil (thyme oil) against human breast cancer. ACS Omega 8(50), 48344\u201348359 (2023).","journal-title":"ACS Omega"},{"issue":"9","key":"52551_CR14","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-21-556","volume":"10","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Effects of interleukin-2 concentration and administration method on proliferation and function of cytokine-induced killer cells. Transl. Cancer Res. 10(9), 3930 (2021).","journal-title":"Transl. Cancer Res."},{"issue":"1","key":"52551_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3233\/BD-220077","volume":"42","author":"S Abou Shousha","year":"2023","unstructured":"Abou Shousha, S. et al. The effect of Fas\/FasL pathway blocking on apoptosis and stemness within breast cancer tumor microenvironment (preclinical study). Breast Dis. 42(1), 163\u201376 (2023).","journal-title":"Breast Dis."},{"issue":"7","key":"52551_CR16","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1158\/1078-0432.CCR-06-2139","volume":"13","author":"SA Siddiqui","year":"2007","unstructured":"Siddiqui, S. A. et al. Tumor-infiltrating Foxp3\u2009\u2212\u2009CD4+ CD25\u2009+\u2009T cells predict poor survival in renal cell carcinoma. Clin. Cancer Res. 13(7), 2075\u201381 (2007).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"52551_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-68098-z","volume":"14","author":"MT Lepore","year":"2024","unstructured":"Lepore, M. T. et al. Deciphering the role of protein kinase A in the control of FoxP3 expression in regulatory T cells in health and autoimmunity. Sci. Rep. 14(1), 17571 (2024).","journal-title":"Sci. Rep."},{"key":"52551_CR18","volume":"7","author":"DM Gaber","year":"2024","unstructured":"Gaber, D. M. et al. A drug repurposing approach of Atorvastatin calcium for its antiproliferative activity for effective treatment of breast cancer: In vitro and in vivo assessment. Int. J. Pharm. X 7, 100249 (2024).","journal-title":"Int. J. Pharm. X"},{"issue":"17","key":"52551_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174287","volume":"13","author":"S \u0141ukasiewicz","year":"2021","unstructured":"\u0141ukasiewicz, S. et al. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel) 13(17), 4287. https:\/\/doi.org\/10.3390\/cancers13174287 (2021).","journal-title":"Cancers (Basel)"},{"issue":"5","key":"52551_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59050957","volume":"59","author":"S Chopra","year":"2023","unstructured":"Chopra, S., Khosla, M. & Vidya, R. Innovations and challenges in breast cancer care: A review. Medicina 59(5), 957. https:\/\/doi.org\/10.3390\/medicina59050957 (2023).","journal-title":"Medicina"},{"issue":"16","key":"52551_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164233","volume":"13","author":"JJ Li","year":"2021","unstructured":"Li, J. J., Tsang, J. Y. & Tse, G. M. Tumor microenvironment in breast cancer-updates on therapeutic implications and pathologic assessment. Cancers (Basel) 13(16), 4233. https:\/\/doi.org\/10.3390\/cancers13164233 (2021).","journal-title":"Cancers (Basel)"},{"issue":"8","key":"52551_CR22","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","volume":"25","author":"S Loi","year":"2014","unstructured":"Loi, S. et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann. Oncol. 25(8), 1544\u201350 (2014).","journal-title":"Ann. Oncol."},{"issue":"2","key":"52551_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov, H., Orhan, A., Christensen, J. P. & G\u00f6genur, I. Cytotoxic CD8\u2009+\u2009T cells in cancer and cancer immunotherapy. Br. J. Cancer. 124 (2), 359\u2013367 (2021).","journal-title":"Br. J. Cancer"},{"key":"52551_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-4441-3","volume":"18","author":"JP Bates","year":"2018","unstructured":"Bates, J. P., Derakhshandeh, R., Jones, L. & Webb, T. J. Mechanisms of immune evasion in breast cancer. BMC Cancer 18, 1\u20134 (2018).","journal-title":"BMC Cancer"},{"issue":"2","key":"52551_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/bfgp\/ely006","volume":"18","author":"QF He","year":"2019","unstructured":"He, Q. F. et al. CD8\u2009+\u2009T-cell exhaustion in cancer: Mechanisms and new area for cancer immunotherapy. Brief. Funct. Genomics 18(2), 99\u2013106 (2019).","journal-title":"Brief. Funct. Genomics"},{"issue":"5","key":"52551_CR26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1158\/2326-6066.CIR-14-0232","volume":"3","author":"SL Shiao","year":"2015","unstructured":"Shiao, S. L. et al. TH2-polarized CD4\u2009+\u2009T cells and macrophages limit efficacy of radiotherapy. Cancer Immunol. Res. 3(5), 518\u201325 (2015).","journal-title":"Cancer Immunol. Res."},{"issue":"7","key":"52551_CR27","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1111\/cas.14069","volume":"110","author":"Y Ohue","year":"2019","unstructured":"Ohue, Y. & Nishikawa, H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?. Cancer Sci. 110(7), 2080\u20139 (2019).","journal-title":"Cancer Sci."},{"key":"52551_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02453","volume":"10","author":"CM Paluskievicz","year":"2019","unstructured":"Paluskievicz, C. M. et al. T regulatory cells and priming the suppressive tumor microenvironment. Front. Immunol. 10, 2453 (2019).","journal-title":"Front. Immunol."},{"issue":"12","key":"52551_CR29","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s00262-017-2053-4","volume":"66","author":"F Bengsch","year":"2017","unstructured":"Bengsch, F., Knoblock, D. M., Liu, A., McAllister, F. & Beatty, G. L. CTLA-4\/CD80 pathway regulates T cell infiltration into pancreatic cancer. Cancer Immunol. Immunother. 66 (12), 1609\u20131617 (2017).","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"52551_CR30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1084\/jem.20041982","volume":"201","author":"R Setoguchi","year":"2005","unstructured":"Setoguchi, R., Hori, S., Takahashi, T. & Sakaguchi, S. Homeostatic maintenance of natural Foxp3\u2009+\u2009CD25+ CD4\u2009+\u2009regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201 (5), 723 (2005).","journal-title":"J. Exp. Med."},{"key":"52551_CR31","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fimmu.2012.00268","volume":"3","author":"T H\u00f6fer","year":"2012","unstructured":"H\u00f6fer, T., Krichevsky, O. & Altan-Bonnet, G. Competition for IL-2 between regulatory and effector T cells to chisel immune responses. Front. Immunol. 3, 268 (2012).","journal-title":"Front. Immunol."},{"issue":"6","key":"52551_CR32","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/eji.200737791","volume":"38","author":"S Brandenburg","year":"2008","unstructured":"Brandenburg, S. et al. IL\u20102 induces in vivo suppression by CD4\u2009+\u2009CD25+ Foxp3\u2009+\u2009regulatory T cells. Eur. J. Immunol. 38(6), 1643\u201353 (2008).","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"52551_CR33","first-page":"7816","volume":"8","author":"Y Li","year":"2015","unstructured":"Li, Y. et al. Interleukin-2 administration after modified radical mastectomy in breast cancer therapy increases peripheral regulatory T cells. Int. J. Clin. Exp. Med. 8(5), 7816\u201322 (2015).","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"1","key":"52551_CR34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/CJI.0b013e3182372636","volume":"35","author":"RW Joseph","year":"2012","unstructured":"Joseph, R. W. et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J. Immunother. 35(1), 66\u201372 (2012).","journal-title":"J. Immunother."},{"issue":"2","key":"52551_CR35","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.immuni.2009.06.021","volume":"31","author":"A Kallies","year":"2009","unstructured":"Kallies, A., Xin, A., Belz, G. T. & Nutt, S. L. Blimp-1 transcription factor is required for the differentiation of effector CD8\u2009+\u2009T cells and memory responses. Immunity 31 (2), 283\u2013295 (2009).","journal-title":"Immunity"},{"issue":"5","key":"52551_CR36","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3109\/10428194.2014.953155","volume":"56","author":"M Boi","year":"2015","unstructured":"Boi, M., Zucca, E., Inghirami, G. & Bertoni, F. PRDM1\/BLIMP1: A tumor suppressor gene in B and T cell lymphomas. Leuk. Lymphoma 56(5), 1223\u20131228 (2015).","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"52551_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.immuni.2019.12.007","volume":"52","author":"A \u015aledzi\u0144ska","year":"2020","unstructured":"\u015aledzi\u0144ska, A. et al. Regulatory T cells restrain interleukin-2-and Blimp-1-dependent acquisition of cytotoxic function by CD4\u2009+\u2009T cells. Immunity 52(1), 151\u201366 (2020).","journal-title":"Immunity"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52551-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52551-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52551-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:34:16Z","timestamp":1779802456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52551-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["52551"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-52551-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The ethical committee at Alexandria University\u2019s medical research institute in Egypt gave its approval to the current study (E\/C. S\/N. T81\/2017), which complies with the Declaration of Helsinki\u2019s guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"\u201cInformed consent was obtained from all individual participants included in the study.\u201d","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"16296"}}